Published Date: 08 Mar 2023
Atorvastatin 40 mg daily for 12 months reduces cardiovascular events in lymphoma patients treated with anthracyclines.
Read Full NewsA phase 2 study at CTAD 2025 explores VHB937's potential in treating early Alzheimer disease, focusing on safety and efficacy in patients.
In an analysis of the phase 2a CLEAR MIND study presented at CTAD 2025, laromestrocel treatment was associated with reduced hippocampal neuroinflammation in patients with mild Alzheimer disease.
A new phase 3 clinical trial is underway to evaluate masupirdine, a selective 5-HT6 receptor antagonist, as a potential treatment for agitation in patients with Alzheimer’s disease.
Pulmonary Rehabilitation Reduces Type 2 Inflammation in High Inflammation Asthma
Mental Health Apps Gain High Uptake but Struggle With Adherence, Retention
6 Ophthalmology Headlines You Missed in October 2025
1.
Geriatric Assessment, QoL Correlate With OS in Older Patients with Pancreatic Cancer
2.
Chronic stress and obesity work together to accelerate pancreatic cancer development and growth, study finds
3.
AI-based breast cancer risk technology receives FDA breakthrough device designation
4.
Study Finds Actionable Mutations in Brain Mets of Breast Cancer Patients
5.
'Full House' Star's Cancer; Fluoride Fears Go Mainstream; Florida Doctor Arrested
1.
Clinical Analysis of Prostate Cancer
2.
The Predictive Power of Theranostics in Palliative Neuroendocrine Tumor Management
3.
Precision Oncology: Personalized Medicine Shaping the Future of Cancer Care
4.
Unlocking the Potential of Immune Checkpoint Inhibitors: A Pioneering Case Series on the Role of Immunotherapy in Microsatellite-Instability-High Colorectal Cancer
5.
Understanding Melanoma: From Diagnosis to Healing and Excision in Denver
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis
2.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
3.
Newer Immunotherapies for Myeloma- A Comprehensive Overview- Part II
4.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Summarization of the New Perspective
5.
Efficient Management of First line ALK-rearranged NSCLC - Part VI
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation